Plain-English translation of NCT06709417 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called — an immunotherapy drug — combined with and radiation to treat advanced esophageal squamous cell carcinoma (a specific type of esophageal cancer). The study is designed for patients whose cancer is too advanced or spread in ways that make it difficult to operate on at first. Researchers want to see if this treatment can shrink the cancer enough to make surgery possible, or control it without surgery.
Advanced esophageal cancers that cannot be immediately operated on have limited treatment options and poor survival rates. This trial is testing whether adding this medication — which helps the body's immune system fight cancer — to standard and radiation can improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You would start by receiving two cycles of the medication combined with drugs. After this, doctors will assess whether your cancer has shrunk enough for surgery. If you can have surgery, you'll undergo the operation followed by up to a year of additional medication treatment. If surgery isn't possible at that point, you'll receive radiation therapy combined with , followed by another evaluation for surgery a few weeks later. Throughout the process, you'll have regular clinic visits, imaging scans, and blood tests to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China